Drug development should rely on fewer, larger trials, ex-Lilly exec Thompson tells FDA.
DRUG DEVELOPMENT SHOULD RELY ON FEWER, LARGER STUDIES, ex-LILLY EXEC Leigh Thompson, MD/PhD, suggested at a Feb. 5 Center for Drug Evaluation & Research seminar. "We can get very few, large, well-designed, complex studies that have far more power in terms of the analyses we do and not have all of these small wasteful studies exposing people to placebo and doses that aren't any good," Thompson said. He advised FDA to "teach industry how to do a small number of studies" and to "coach people to think beyond mean and standard deviation."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth